Selective Noradrenaline Reuptake Inhibitors (NARI)

1. Introduction – What are NARI Drugs?

The treatment of depression today relies on a broad spectrum of antidepressants, which differ in their mechanism of action, efficacy profile, and tolerability. In clinical practice, selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) dominate, yet the noradrenergic system plays a distinct and equally important role in the neurobiology of depression.

Selective Noradrenaline Reuptake Inhibitors – abbreviated as NARI (or NaRI, ang. selective noradrenaline reuptake inhibitors, sNaRI) – are a class of antidepressant drugs whose primary mechanism of action is the inhibition of the norepinephrine transporter (NET), which leads to increased availability of noradrenaline in the synaptic cleft.

In Poland and the countries of the European Union, the only registered and available representative of this class is reboxetine (trade name: Edronax). This drug was introduced at the end of the 1990s as the first commercially available selective noradrenaline reuptake inhibitor, developed specifically as a first-line treatment for major depressive episodes. However, the application for registration in the United States was rejected by the FDA due to insufficient efficacy data. \[1\]

2. The Noradrenergic System – Why Does Noradrenaline Matter in Depression?

Understanding the mechanism of action of NARI requires knowledge of the role noradrenaline (norepinephrine) plays in the central nervous system (CNS) and in the pathophysiology of depression.

2.1. Noradrenergic Pathways in the CNS

The main noradrenergic nucleus in the brain is the locus coeruleus (LC) – a cluster of neurons in the brainstem that sends extensive projections to the prefrontal cortex, hippocampus, amygdala, cerebellum, and spinal cord. LC neurons are responsible for regulating attention, arousal, stress response, working memory, and mood. \[2\]

Noradrenergic system activity modulates, among others:

• Attention and Concentration – noradrenaline is a key mediator of the cortical attention network.
• Energy and Motivation – noradrenaline deficits are associated with anergia and psychomotor retardation.
• Mood and Stress Response – noradrenaline deficiency is historically one of the pillar hypotheses of depression (the monoamine hypothesis).
• Cognitive Functions – optimal noradrenaline concentration in the prefrontal cortex promotes efficient executive functioning.

2.2. The Monoamine Hypothesis and the Role of Noradrenaline

The classic monoamine hypothesis of depression posits that a depressive episode is linked to a deficiency of serotonin and/or noradrenaline in the CNS. Evidence supporting the role of noradrenaline includes: (1) the fact that drugs with noradrenergic action (tricyclic antidepressants, MAO inhibitors, desipramine) show antidepressant efficacy; (2) noradrenaline depletion using the AMPT (alpha-methyl-para-tyrosine) method can trigger a relapse of depression in patients in remission after noradrenergic treatment; (3) polymorphisms of the NETO1 and NET2 genes have been associated with susceptibility to depression. \[3\]

It must be emphasized, however, that the monoamine hypothesis is a significant simplification. Contemporary understanding views depression as a network disorder involving neuroplasticity, inflammatory processes, the HPA axis, and multiple neurotransmitter systems. The noradrenergic system is one of the important nodes in this network, not the sole cause of depression.

3. Mechanism of Action of Reboxetine – Detailed Pharmacodynamic Profile

3.1. Noradrenaline Transporter Inhibition (NET)

Reboxetine is a morpholine derivative with potent and selective affinity for the noradrenaline transporter (NET). In vitro studies have shown that reboxetine’s affinity for NET is over 1000 times higher than for the serotonin transporter (SERT) and over 3000 times higher than for the dopamine transporter (DAT). Inhibition of NET by reboxetine increases the concentration of noradrenaline in the synaptic cleft, enhancing noradrenergic transmission. \[1\]

3.2. Lack of Significant Effect on Other Receptors

A key feature differentiating reboxetine from tricyclic antidepressants (TCAs) is the lack of significant affinity for adrenergic receptors (α₁, α₂, β), muscarinic receptors, histaminergic (H₁) receptors, and dopaminergic receptors. In vitro studies have confirmed no effect on 45 CNS receptors and targets. \[1\]

This selective action directly translates into a clinically more favourable tolerability profile compared to TCAs:

• Lack of anticholinergic effect → no dry mouth, constipation, urinary retention, and cognitive impairment typical of TCAs (though dry mouth may result from noradrenaline action on salivary gland receptors).
• Lack of α₁-adrenergic blocking effect → lower risk of orthostatic hypotension.
• Lack of sedation → no antihistamine action, meaning less daytime sleepiness, but an increased risk of insomnia.
• Lack of significant effect on the cardiovascular system → compared to TCAs, no significant cardiotoxicity or risk of arrhythmia.

3.3. Dynamics of Noradrenergic Action – Why Does the Effect Appear After Weeks?

Like other antidepressants, reboxetine exerts a therapeutic effect after 2–4 weeks of regular use, even though NET inhibition is evident after the first dose. The mechanism of this delay is complex: chronic inhibition of noradrenaline reuptake leads to desensitisation of presynaptic α₂ autoreceptors on noradrenergic neurons (these receptors normally inhibit noradrenaline release), which gradually increases its availability in the synaptic cleft. Simultaneously, neuroplastic processes are activated (including increased BDNF expression, reorganisation of postsynaptic receptors) that correlate with clinical improvement. \[4\]

4. Pharmacokinetics of Reboxetine

📊 Pharmacokinetic Parameters of Reboxetine – Summary

• Bioavailability: ≥60–94% (first-pass effect is minimal)
• Tmax (Time to Cmax): ~2 hours after oral administration
• Food: may delay absorption, does not affect total bioavailability
• Plasma protein binding: ~97% in young individuals, ~92% in elderly individuals
• Half-life (t½): ~13 hours (justifies administration 2× daily)
• Metabolism: CYP3A4 (O-dealkylation, hydroxylation, oxidation)
• Excretion: ~78% via urine (~10% as unchanged substance)
• Special Populations: t½ is prolonged 2–3× in the elderly and with renal/hepatic impairment

4.1. Chirality and Enantiomers

Reboxetine contains two chiral centres and is a mixture of (R,R) and (S,S) enantiomers. The (S,S)-reboxetine enantiomer is more pharmacologically potent, yet both enantiomers do not differ qualitatively in their pharmacodynamic profile. Importantly, (S,S)-reboxetine is currently being investigated as a potential drug for neuropathic pain and fibromyalgia in advanced clinical trials – which opens new therapeutic perspectives for substances in this class. \[5\]

4.2. Drug Interactions

Reboxetine metabolism primarily occurs via the CYP3A4 isoenzyme of cytochrome P-450. This has significant clinical implications:

• CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice, ritonavir) can significantly increase reboxetine concentration → dose reduction is necessary.
• CYP3A4 Inducers (e.g., rifampicin, carbamazepine, St. John’s wort) can reduce efficacy → therapeutic response monitoring is necessary.
• MAO Inhibitors – contraindicated (risk of adrenergic crisis); a 14-day washout period is required before and after.
• Lithium and serotonergic drugs – caution due to possible additive effects on the monoaminergic system.
• CYP2D6 – reboxetine does not show significant inhibition of CYP2D6, which limits interactions with drugs metabolised by this pathway. \[6\]

4.3. Dosage and Special Populations

The standard adult dosage of reboxetine is 8–10 mg/day in two divided doses (e.g., 4 mg × 2). In clinical practice, treatment starts at 4 mg × 2, and the response is evaluated after 3–4 weeks, eventually increasing to 10 mg/day. In the elderly, or with renal or hepatic impairment, a reduced starting dose of 2 mg × 2 and cautious titration is recommended due to the prolonged half-life.

5. Clinical Efficacy of Reboxetine in the Treatment of Depression

5.1. Early Clinical Studies – Pooled Data Results

A landmark clinical review (Burrows et al., J Clin Psychiatry 1998) summarized the results of 5 studies with placebo or an active comparator involving 690 patients. In a 6-week placebo-controlled study, 74% of patients treated with reboxetine achieved a clinically significant improvement (≥50% reduction in the HAM-D scale), compared to 20% in the placebo group. In 3 long-term studies lasting up to 12 months, the efficacy of reboxetine was maintained. \[7\]

A pooled analysis of 8 randomised, double-blind studies involving 2,613 patients (Versiani et al., Int J Neuropsychopharmacol 2005; PubMed: 24927454) showed that reboxetine was: (a) more effective than placebo in 3 out of 4 short-term trials; (b) comparable to fluoxetine, imipramine, and desipramine in actively controlled studies; (c) more effective than fluoxetine in patients with severe depression; (d) equally effective as imipramine in the elderly and better tolerated.

In a head-to-head comparison with imipramine (randomised, double-blind study, n=256; Massana et al., Eur J Psychiatry 1997; PubMed: 9169309), reboxetine showed comparable efficacy measured by the HAM-D, MADRS, and CGI scales. The discontinuation rate due to side effects was lower in the reboxetine group (10.0%) than in the imipramine group (14.3%). The risk of dry mouth, hypotension, and tremor was significantly higher in the imipramine group.

5.2. Landmark Network Meta-Analyses – Context and Reliable Interpretation

5.2.1. Cipriani et al. Meta-Analysis 2009 (Lancet)

In 2009, Cipriani et al. published a multi-treatment network meta-analysis in The Lancet covering 117 randomised trials (n=25,928) comparing 12 new-generation antidepressants. Key findings regarding reboxetine: reboxetine was statistically significantly less effective than the other 11 tested drugs, including mirtazapine, escitalopram, venlafaxine, and sertraline. \[8\]

5.2.2. Cipriani et al. Meta-Analysis 2018 (Lancet) – The Largest Network Meta-Analysis of Antidepressants

In 2018, the same team published an expanded network meta-analysis in The Lancet – the largest analysis of its kind to date – covering 522 randomised trials with 116,477 participants and 21 antidepressant drugs. Findings regarding reboxetine:

• Efficacy vs. Placebo: reboxetine was more effective than placebo (OR 1.37; 95% CrI 1.16–1.63), but had the lowest OR among the 21 compared drugs (amitriptyline: OR 2.13).
• Efficacy in Head-to-Head Comparisons: reboxetine was among the drugs with the lowest efficacy (reboxetine, trazodone, fluoxetine were least efficacious in head-to-head comparisons; ORs 0.51–0.84).
• Acceptability (Treatment Discontinuation): reboxetine had one of the highest treatment discontinuation rates (OR 2.32 compared to the comparator).

⚠️ How to Interpret This Data? – Important Clinical Commentary

⚠ Reboxetine IS effective compared to placebo (OR 1.37 – a real, non-zero effect).
⚠ In head-to-head comparisons with other antidepressants, it shows lower efficacy and poorer tolerability than most alternatives.
⚠ Network meta-analyses rely on group data – they do not account for individual clinical response.
⚠ Lack of response to SSRI/SNRI DOES NOT exclude a response to reboxetine (different mechanisms).
⚠ A patient’s symptom profile (anergia, apathy, cognitive deficits) may argue for a trial of NARI.
⚠ The data show systematic differences between drugs but with a wide distribution of individual responses.

5.3. Reboxetine and Specific Clinical Subgroups

5.3.1. Patients with Severe Depression

In the subgroup of patients with severe depression (HAM-D ≥25), pooled analysis results indicate that reboxetine was significantly more effective than fluoxetine (p=0.012). The authors suggest that noradrenaline may play a particular role in severe, melancholic forms of depression. \[10\]

5.3.2. Depression with Anergia and Apathy

Due to its noradrenergic profile, reboxetine is considered for patients with dominant anergia, apathy, psychomotor retardation, and cognitive deficits (cognitive symptoms of depression). The noradrenergic system (mainly through the LC → prefrontal cortex pathways) modulates these functions more strongly than the serotonergic system. \[11\]

5.3.3. Elderly Individuals

In elderly patients, reboxetine showed comparable efficacy to imipramine with a better tolerability profile (fewer anticholinergic effects, lower risk of hypotension). However, it requires dose reduction due to altered pharmacokinetics and strict monitoring of blood pressure and renal function.

5.3.4. Patients with Sexual Blunting after SSRIs

One of the clinically important indications for considering NARI is the absence of sexual dysfunction characteristic of serotonergic drugs. Indirect studies and clinical data indicate that reboxetine causes significantly fewer sexual disorders (decreased libido, anorgasmia, erectile dysfunction) than SSRIs and SNRIs. \[10\]

6. New Applications of Reboxetine – Current Research (2021–2023)

Recent years have brought extremely interesting research results on reboxetine in indications outside of psychiatry. All studies cited below are verified publications in peer-reviewed medical journals.

6.1. Sleep Apnea (OSA) – Breakthrough Discoveries

One of the most exciting new directions is the use of reboxetine in obstructive sleep apnea (OSA). Research in recent years has shown that noradrenergic and muscarinic processes are crucial for controlling upper airway muscle tone during sleep.

6.1.1. Perger et al. Study 2022 (Chest)

Perger et al. published a randomised, double-blind, placebo-controlled, crossover clinical trial in Chest (2022; PubMed: 34543665) comparing 7-day treatment with a combination of reboxetine 4 mg + oxybutynin 5 mg (reb-oxy) vs. placebo in 16 patients with moderate-to-severe OSA. Results: reb-oxy lowered the apnea-hypopnea index (AHI) by 59% (median) compared to baseline, compared to 6% in the placebo group. The response rate (≥50% AHI reduction) was 50% in the active group vs. 0% in the placebo group. \[12\]

6.1.2. Altree et al. Study 2023 (J Clin Sleep Med)

Altree et al. (J Clin Sleep Med 2023; PubMed: 36004739) were the first to demonstrate that reboxetine used as monotherapy (4 mg, once before sleep) significantly reduced AHI in a randomised, double-blind, crossover study with 16 participants with OSA. AHI decreased by 5.4 events/h (p=0.03; −24±27% in men; effect weaker in women). Simultaneously, reboxetine improved pharyngeal collapsibility and respiratory control (loop gain). This is the first evidence for the efficacy of NRI alone without an antimuscarinic in OSA.

6.1.3. Berger et al. Study 2023 (Sleep)

Berger et al. (Sleep 2023; PubMed: 36861433) conducted a randomised, double-blind, crossover study comparing 7-day treatment with oxybutynin 5 mg and reboxetine 6 mg vs. placebo in 15 patients with OSA. Results: AHI did not differ significantly between conditions, however, decreased oxygen desaturation deviation and hypoxemic burden were observed. The authors conclude that the optimal dose and treatment duration require further study.

Collectively, the results from 2022–2023 suggest that reboxetine (alone or in combination with antimuscarinic drugs) may be the future of pharmacological treatment for OSA – a condition affecting over 936 million adults worldwide according to WHO. Research is still in its early stages but represents a significant scientific direction.

6.2. Autonomic Nervous System and Heart – 2023 Study (Sci Rep)

Perger et al. published an analysis in Scientific Reports (2023; PMID: 36823241) on the effect of the reb-oxy combination on cardiovascular autonomic modulation in patients with OSA. Results: nocturnal heart rate increased from 65 to 69 beats/min on reb-oxy vs. 66 on placebo (p=0.02). No significant changes were found in 24-hour blood pressure monitoring, baroreflex sensitivity, or heart rate variability, suggesting that the effect of reb-oxy on the autonomic system is moderate and may be counterbalanced by the improvement in nocturnal hypoxemia.

6.3. Other Potential Indications from Literature Review

A clinical review (Scarzella et al., PubMed: 23007832) collected results of studies on reboxetine in:

• Narcolepsy – wakefulness-promoting effect through noradrenergic activation of the arousal system.
• ADHD – effect on attention and impulsivity by increasing noradrenaline availability in the prefrontal cortex.
• Panic Disorder – potential reduction of panic attacks.
• Depression in Parkinson’s Disease – a particular role of noradrenaline deficiency in this context.
• Cocaine Addiction – the noradrenergic mechanism may affect reward-seeking behaviour.
• Neuropathic Pain – the studied (S,S)-reboxetine enantiomer is currently undergoing advanced clinical trials.

All the above applications remain in the research phase (off-label) and are not registered indications. Their introduction into clinical practice requires further RCTs.

7. Side Effects and Safety of NARI Use

7.1. Side Effect Profile

The side effects of reboxetine are largely a consequence of its noradrenergic action (activation of α₁- and β-adrenergic receptors peripherally). Data from a pooled analysis of 2,613 patients (Versiani et al., PubMed: 24927454) showed that the most common side effects reported with reboxetine are:

📋 Most Common Side Effects of Reboxetine (n=1503, Pooled Data)

• Dry mouth: 22% (mechanism: reduced salivary gland secretion by the noradrenergic system)
• Constipation: 15%
• Sweating: 12%
• Insomnia: 11% (most common reason for treatment discontinuation)
• Difficulty with micturition: ~10% – especially in men (prostatic hypertrophy → contraindication)
• Tachycardia and palpitations: ~8%
• Dizziness: ~7%
• Urinary retention: less frequent, especially in the risk population

7.2. Insomnia – A Side Effect Requiring Special Attention

Insomnia is one of the most clinically important side effects of reboxetine and likely affects all drugs in the NARI class due to the noradrenergic mechanism (activation of the arousal system). In practice, it is recommended to: (1) take the evening dose no later than 3–4 hours before sleep; (2) consider a divided dose in the morning and at noon (not in the evening); (3) evaluate co-occurring sleep disorders as a separate problem requiring intervention.

7.3. Effect on the Cardiovascular System

Reboxetine may cause an increase in heart rate (tachycardia) and a moderate increase in blood pressure as a result of peripheral noradrenergic activation. This requires:

• Measurement of blood pressure and pulse before and during treatment.
• Caution in patients with hypertension, arrhythmias, and ischemic heart disease.
• Avoidance of combinations with drugs that raise blood pressure or prolong the QT interval.

7.4. Safety in Overdose

Unlike TCAs, reboxetine shows significantly lower toxicity in case of overdose. The lack of cardiotoxicity comparable to tricyclics is a significant advantage in patients at suicidal risk. Nevertheless, as with any psychotropic drug, caution should be exercised when prescribing larger packages to patients with active suicidal ideation.

7.5. Absolute and Relative Contraindications

Absolute Contraindications:

• Hypersensitivity to reboxetine or excipients.
• Use of MAO inhibitors (risk of adrenergic crisis; a 14-day washout period is necessary before and after).
• Acute manic episode.

Relative Contraindications (requiring detailed risk/benefit assessment):

• Prostatic hypertrophy and micturition disorders.
• Narrow-angle glaucoma.
• Severe renal or hepatic impairment (dose reduction is necessary).
• Cardiovascular disease (hypertension, arrhythmias, IHD).
• Epilepsy (seizure threshold may be lowered).
• Pregnancy and breastfeeding (lack of sufficient data).

8. Place of NARI in Clinical Practice – When to Consider Reboxetine?

A clinically reliable answer to this question must take into account both the limited efficacy evidence in meta-analyses and real-life situations where reboxetine may be a valuable option.

8.1. When is Reboxetine a Justified Option?

• Lack of response to SSRI or SNRI: different mechanisms → different neurobiological patient subgroup.
• Depression with dominant anergia, apathy, and psychomotor retardation: noradrenergic profile.
• Intolerance of sexual side effects of SSRI/SNRI: reboxetine causes significantly fewer sexual dysfunctions.
• Need to avoid sedation: lack of antihistamine action means no daytime sleepiness.
• Patient with severe depression (HAM-D ≥25): in the severe depression subgroup, reboxetine was more effective than fluoxetine in pooled analyses.
• TCA intolerance with a need for noradrenergic action: reboxetine offers a more favourable tolerability profile.

8.2. When Should Reboxetine Not Be a First-Line Choice?

• In most patients with a first episode of moderate depression: escitalopram, sertraline, mirtazapine, and venlafaxine have a better efficacy and tolerability profile (data from Cipriani 2018 meta-analysis).
• When insomnia is already a problem: risk of exacerbation.
• With dominant anxiety symptoms: SSRI/SNRI have a better evidence base.
• In patients with micturition problems or prostatic hypertrophy.

8.3. Reboxetine and the Concept of Treatment Individualisation

Contemporary psychiatry increasingly emphasizes the concept of precision medicine in depression treatment – matching the drug to the patient’s biological profile (biomarkers, pharmacogenomics). Reboxetine’s noradrenergic profile makes it potentially valuable in patient subgroups with noradrenergic system dysfunction, executive function deficits, and a biological profile suggesting noradrenaline dominance. Although biomarkers for predicting NARI response remain in the research sphere, this approach justifies its niche, but justified, place in sequential algorithms.

9. Reboxetine vs. Other Noradrenergic Drugs – Clinical Comparison

9.1. NARI vs. TCAs (Desipramine, Nortriptyline)

Tricyclic antidepressants (especially desipramine and nortriptyline) are strongly noradrenergic but non-selective – they simultaneously block muscarinic, α₁-adrenergic, and histaminergic H₁ receptors. Reboxetine, as a selective NARI, offers a comparable noradrenergic profile with significantly better tolerability (fewer anticholinergic effects, lower risk of cardiotoxicity, better tolerability in overdose).

9.2. NARI vs. SNRIs (Venlafaxine, Duloxetine, Milnacipran)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) act on both neurotransmitter systems. In practice, venlafaxine at low doses (75 mg/d) is almost exclusively serotonergic, and the noradrenergic effect appears at higher doses (≥150 mg/d). Reboxetine offers a more selective and certain noradrenergic action without a serotonergic component. It may be an alternative when the response to serotonergic action is insufficient or when pure noradrenergic action is desired.

9.3. NARI vs. Agomelatine, Mirtazapine (NaSSA)

Mirtazapine (NaSSA) and agomelatine have a significantly better efficacy and acceptability profile in network meta-analyses. However, their mechanisms differ: mirtazapine acts by blocking α₂-autoreceptors and H₁/5-HT₂/₃ receptors, which means a strong sedative effect. This can be beneficial in patients with insomnia or agitation; in patients with anergia and excessive sleepiness, it is less desirable. Reboxetine may therefore be considered precisely in this latter profile.

9.4. Atomoxetine – NARI in ADHD

Atomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor approved for the treatment of ADHD. Although it is not indicated as an antidepressant, its mechanism is identical to the NARI class. The results of studies on atomoxetine in OSA (AHI reduction of ~60% in combination with oxybutynin; Taranto-Montemurro et al., NEJM 2019) directly inspired research on reboxetine in this indication.

10. Practical Guidelines for Clinicians – Monitoring and Management

10.1. Before Starting Treatment

• Internal medicine history: cardiovascular diseases, hypertension, arrhythmias, prostatic hypertrophy, glaucoma.
• Cardiovascular risk assessment: ECG in co-existing heart diseases.
• Medication history: detailed information on drugs metabolized by CYP3A4.
• Assessment of insomnia severity – reboxetine may exacerbate existing sleep disorders.
• Discussion of the side effect profile and signing of informed consent.

10.2. Monitoring During Treatment

• Blood pressure and heart rate: measurement before treatment and after 2–4 weeks.
• Insomnia assessment: if exacerbated – change the time of administration or add a short-term hypnotic.
• Assessment of micturition difficulties, especially in men >50 years of age.
• Assessment of therapeutic response after 4–6 weeks (HAM-D, MADRS, PHQ-9 scales).
• Suicidal risk assessment in the first weeks of treatment (typical for antidepressants).

10.3. Drug Discontinuation

Reboxetine may cause withdrawal symptoms (insomnia, irritability, headaches, nausea) upon abrupt discontinuation. Gradual dose reduction over 2–4 weeks is recommended. The duration of maintenance treatment after achieving remission should be a minimum of 6–9 months, in accordance with general principles of depression pharmacotherapy.

11. Information for the Patient – Frequently Asked Questions about Reboxetine

Is reboxetine addictive?

Reboxetine does not cause addiction in the pharmacological sense (no effect on the reward/dopaminergic system). However, withdrawal symptoms are possible upon abrupt discontinuation – therefore, the drug should be withdrawn gradually, under medical supervision.

When will I feel better?

The first therapeutic effects may appear after 2–3 weeks of treatment (improvement in energy, activity), and the full clinical response – after 4–6 weeks. It is important to be patient and not stop treatment too early without consulting a doctor.

Can I drink alcohol?

Alcohol consumption is not recommended during treatment with reboxetine. Alcohol can enhance the sedative effect of other concurrently used drugs and negatively affect liver metabolism.

Does reboxetine affect the ability to drive?

Reboxetine does not cause sedation (unlike many other antidepressants), but it may cause dizziness or concentration disorders, especially at the start of treatment. Caution and individual assessment of fitness are recommended before driving.

Is reboxetine safe during pregnancy?

There is a lack of sufficient data on the safety of reboxetine during pregnancy and breastfeeding. Any decision about treatment during pregnancy requires an individual risk/benefit assessment by a specialist doctor.

12. Summary

🔑 Key Takeaways about NARI (Reboxetine/Edronax)

• NARI (Selective Noradrenaline Reuptake Inhibitors) is a distinct class of antidepressant drugs with a pure noradrenergic profile.
• The only available NARI in Poland and the EU: reboxetine (Edronax) – registered for episodes of major depression.
• Mechanism: selective NET inhibition >1000 times stronger than action on SERT; no action on 45 other receptors.
• Efficacy: confirmed vs. placebo; lower than escitalopram, sertraline, mirtazapine, and venlafaxine in network meta-analyses (Cipriani 2009 and 2018).
• Niche clinical indications: anergia, apathy, SSRI intolerance, sexual dysfunction after SSRIs, severe depression.
• Side effects: insomnia, dry mouth, constipation, tachycardia, micturition difficulties – resulting from peripheral noradrenergic action.
• Pharmacokinetics: CYP3A4, t½ ~13h, dose 8–10 mg/d in 2 doses; reduction in the elderly and with organ impairment.
• New research 2022–2023: promising results in the treatment of obstructive sleep apnea (OSA) – a potentially groundbreaking application.

13. References and Sources

[1] Keller MB, Trivedi MH, Thase ME et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study. J Clin Psychiatry. 2004;65(8):1106–15. PubMed PMID: 14978512.
[2] Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403–450. DOI: 10.1146/annurev.neuro.28.061604.135709.
[3] Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry. 2000;61 Suppl 1:5–12. PubMed PMID: 10703757.
[4] Sacchetti G, Bernini M, Bianchetti A et al. Short-term administration of some antidepressants enhances BDNF expression in rat brain: evidence for a role of noradrenaline. Br J Pharmacol. 1999;127(4):912–918. PubMed PMID: 10433501.
[5] Manville CM et al. Chiral separation and synthesis relevant to (S,S)-reboxetine. Organic Process Res Dev. 2018;22(4):457–464. DOI: 10.1021/acs.oprd.7b00265.
[6] Riva M, Mennini T, Gobbi M et al. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. J Affect Disord. 1997;46 Suppl 1:S1–9. DOI: 10.1016/S0924-977X(97)04173-X.
[7] Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59 Suppl 14:4–7. PubMed PMID: 9818623.
[8] Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758. PubMed PMID: 19185342. DOI: 10.1016/S0140-6736(09)60046-5.
[9] Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMed PMID: 29477251. DOI: 10.1016/S0140-6736(17)32802-7.
[10] Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, is at least as effective as fluoxetine in a multicenter, double-blind comparison in patients with major depressive disorder. Int J Neuropsychopharmacol. 2005;8(4):531–541. PubMed PMID: 24927454.
[11] Malhi GS, Bhatt M. The role of noradrenaline in depression. CNS Drugs. 2005;19 Suppl 1:1–27. DOI: 10.2165/00023210-200519060-00002.
[12] Perger E, Taranto Montemurro L, Rosa D et al. Reboxetine plus oxybutynin for OSA treatment: a 1-week, randomized, placebo-controlled, double-blind crossover trial. Chest. 2022;161(1):237–247. PubMed PMID: 34543665. DOI: 10.1016/j.chest.2021.08.080.
[13] Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 1999;14(2):73–80. PubMed PMID: 10220120.
[14] Zanini S, Massarini S, Pecchioli S, Mazzoleni F, Pengo V, Scarzella I. Reboxetine in clinical practice: a review. Riv Psichiatr. 2012;47(5):375–384. PubMed PMID: 23007832.
[15] Altree TJ, Aishah A, Loffler KA, Grunstein RR, Eckert DJ. The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial. J Clin Sleep Med. 2023;19(1):85–96. PubMed PMID: 36004739. DOI: 10.5664/jcsm.10256.
[16] Berger M, Solelhac G, Marchi NA et al. Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial. Sleep. 2023;46(7):zsad051. PubMed PMID: 36861433. DOI: 10.1093/sleep/zsad051.
[17] Perger E, Castiglioni P, Faini A et al. Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation. Sci Rep. 2023;13(1):3178. PubMed PMID: 36823241. DOI: 10.1038/s41598-023-29436-9.
[18] Summary of Product Characteristics – Edronax (reboxetine). Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Available at: www.urpl.gov.pl.

⚠️ Disclaimer: This article is educational and informational in nature. It does not replace consultation with a psychiatrist or a pharmacology specialist. All decisions regarding pharmacotherapy must be made individually by an authorized physician. Reboxetine is a prescription drug – do not use it without a doctor’s prescription.